Literature DB >> 28444337

Utility of a repeat renal biopsy in lupus nephritis: a single centre experience.

Angela Pakozdi1, Debasish Pyne1, Michael Sheaff2, Ravindra Rajakariar3.   

Abstract

Background: The role of repeat renal biopsy in lupus nephritis (LN) to guide treatment or predict prognosis has been controversial. We assessed glomerular and tubulointerstitial histological characteristics of serial renal biopsies, correlations with clinical variables and the impact on subsequent management.
Methods: Out of a large single-centre cohort of 270 biopsy-proven LN patients, 66 (24%) had serial biopsies. LN classes based on glomerular pathology were defined according to the International Society of Nephrology/Renal Pathology Society 2003 classification, while tubulointerstitial pathologies were evaluated using the revised Austin's semi-quantitative scoring system.
Results: LN class transitions from proliferative (III and IV) to non-proliferative classes (II and V) were uncommon (n = 4, 7.7%), while non-proliferatives frequently switched to proliferative classes (n = 12, 63.2%) and were more likely to receive increased immunosuppression (P = 0.040). Biochemical or serological variables could not predict these histopathological transitions. Tubulointerstitial score (mean ± standard deviation) progressed from 2.69 ± 2.03 on reference to 3.78 ± 2.03 on repeat biopsy (P = 0.001). Serum creatinine levels correlated with the degree of tubular atrophy on both reference (r = 0.33, P = 0.048) and repeat biopsy (r = 0.56, P < 0.001), and with interstitial scarring (r = 0.60, P < 0.001) on repeat biopsy. Greater interstitial inflammation on reference biopsy was associated with advanced interstitial scarring on repeat biopsies (r = 0.385, P = 0.009). Conclusions: Repeat renal biopsy is an important tool to guide management, in particular in those with initial class II or V who flare. Although class transitions cannot be predicted by clinical parameters, serum creatinine level correlates with the degree of tubulointerstitial damage.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 28444337     DOI: 10.1093/ndt/gfx019

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

1.  Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience.

Authors:  Emine Duran; Tolga Yıldırım; Arzu Taghiyeva; Emre Bilgin; Mustafa Arıcı; Emine Arzu Sağlam; Seza Özen; Meral Üner; Yunus Erdem; Umut Kalyoncu; Ali Ihsan Ertenli
Journal:  Lupus       Date:  2022-06-03       Impact factor: 2.858

2.  History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis.

Authors:  Andrea Fava; Paride Fenaroli; Avi Rosenberg; Serena Bagnasco; Jessica Li; Jose Monroy-Trujillo; Derek Fine; Mohamed G Atta; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

3.  Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.

Authors:  Gabriella Moroni; Luca Iaccarino; Mariele Gatto; Francesca Radice; Francesca Saccon; Marta Calatroni; Giulia Frontini; Barbara Trezzi; Margherita Zen; Anna Ghirardello; Francesco Tamborini; Valentina Binda; Vincenzo L'Imperio; Andrea Doria; Augusto Vaglio; Renato Alberto Sinico
Journal:  Lupus Sci Med       Date:  2022-05

Review 4.  Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression.

Authors:  Anadi Mahajan; Justyna Amelio; Kerry Gairy; Gavneet Kaur; Roger A Levy; David Roth; Damon Bass
Journal:  Lupus       Date:  2020-06-22       Impact factor: 2.911

5.  Kidney biopsy guidebook 2020 in Japan.

Authors:  Yoshifumi Ubara; Takehiko Kawaguchi; Tasuku Nagasawa; Kenichiro Miura; Takayuki Katsuno; Takashi Morikawa; Eiji Ishikawa; Masao Ogura; Hideki Matsumura; Ryota Kurayama; Shinsuke Matsumoto; Yuhji Marui; Shigeo Hara; Shoichi Maruyama; Ichiei Narita; Hirokazu Okada; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2021-04       Impact factor: 2.801

Review 6.  Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.

Authors:  Mario E Alamilla-Sanchez; Miguel A Alcala-Salgado; Cesar D Alonso-Bello; Gandhy T Fonseca-Gonzalez
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-12-11

7.  High-Throughput Sequencing-Based Analysis of T Cell Repertoire in Lupus Nephritis.

Authors:  Xiaolan Ye; Zhe Wang; Qiang Ye; Jing Zhang; Ping Huang; Jingying Song; Yiwen Li; Hongjuan Zhang; Feifeng Song; Zixue Xuan; Kejian Wang
Journal:  Front Immunol       Date:  2020-08-06       Impact factor: 7.561

8.  The long-term outcomes and histological transformation in class II lupus nephritis.

Authors:  Abdulkareem O Alsuwaida; Amaar A Bakhit; Feras A Alsuwaida; Junaid J Wadera; Hala M Kfoury; Sufia Husain
Journal:  Saudi Med J       Date:  2018-10       Impact factor: 1.484

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.